Durvalumab Improves Event-Free Survival in Resectable Non–Small Cell Lung Cancer
March 15th 2023Adding durvalumab to neoadjuvant chemotherapy to treat resectable early-stage non–small cell lung cancer did not increase complications and adverse events or comprise patients’ ability to undergo surgery versus chemotherapy alone.
Read More
Pharmacy Focus: Student Edition - The Granada Statements
March 13th 2023Shane Desselle, RPh, PhD, FAPhA, associate dean for Research and Professional Affairs at the Touro University California College of Pharmacy, discusses what the Granada Statements are and why they are important for student pharmacists.
Listen
Merck Discontinues Trials of Pembrolizumab in Prostate Cancer, Non–Small Cell Lung Cancer
March 13th 2023The KEYNOTE-641 and -789 trials did not demonstrate improvements or meet the primary endpoints in metastatic castration-resistant prostate cancer and metastatic nonsquamous non–small cell lung cancer.
Read More
FDA Advisory Committee Supports Polatuzumab for Previously Untreated Diffuse Large B-cell Lymphoma
March 10th 2023On April 2, 2023, the FDA will announce the approval status of Roche’s supplemental Biologics License Application for polatuzumab in the treatment of diffuse large B-cell lymphoma.
Read More